In a report released today, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Cara Therapeutics (CARA – Research

In a report released today, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Cara Therapeutics (CARA – Research
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Cara Therapeutics (CARA – Research
On November 19, a Director at Cara Therapeutics (CARA – Research Report), Martin Vogelbaum, sold shares of CARA for $96.54K.
After H.C. Wainwright and Needham gave Cara Therapeutics (NASDAQ: CARA) a Buy rating last month, the company received another Buy,
In a report released today, Alan Carr from Needham reiterated a Buy rating on Cara Therapeutics (CARA – Research Report),
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Cara Therapeutics (CARA – Research Report) today and set a
Needham analyst Alan Carr assigned a Buy rating to Cara Therapeutics (CARA – Research Report) today and set a price